Blog Archives - Page 4 of 12 - Myriad RBM
  • Subscribe to our Blog

    Receive excerpts from our latest posts via email.

  • Categories


    Biomarkers Validated for Acute Kidney Injury (AKI)

    A clinical test measuring tissue inhibitor of metalloproteinases (TIMP)-2 and insulin-like growth factor binding protein 7 (IGFBP7) in urine has been validated to identify patients at risk for impending AKI.

    » Read this post

    CSF Biomarkers Measure Tissue Damage Indicative of Disease Activity in Multiple Sclerosis (MS)

    A recent study shows that three CSF markers, MBP, NFL and GFAp, can measure ongoing damage of oligodendrocytes, axons and astrocytes in patients with MS. This capability can be used to improve current methods of evaluating disease activity.;jsessionid=0BC1364DCBA7F0E3E8C0754031C4D61F.f03t04

    » Read this post

    New Biomarker Offers Hope for Early Detection of Cardiac Injury

    Myocardial infarctions and acute coronary syndrome affect nearly 1 million Americans every year. These events result in damage to the heart tissue and lead to hospitalization with high levels of morbidity and mortality. Cardiac troponin is a biomarker that is elevated in plasma following these events but it lacks the sensitivity to detect early stage […]

    » Read this post

    Tackling Cancer’s Heterogeneity

    This article from GEN suggests tackling cancer’s heterogeneity using a multipronged approach that includes current advancements in the detection of proteomic biomarkers. The goal is to quantify heterogeneity and assist researchers so that they will be better equipped to determine the marker’s biological roles and shape therapeutic strategies.

    » Read this post

    Researchers Identify Signature Protein Biomarkers for Predicting Severity in Flu Cases

    Investigators observed samples from 84 naturally influenza-infected individuals and found increased levels of cytokines MCP-3, IFNa2 and plasma IL-10 predicted progression to more severe flu symptoms. While increased levels of plasma IL-10, MCP-3 and IL-6 levels predicted hospitalization. The findings from this paper also explain why infants are at high risk for complications, and why […]

    » Read this post

    A Digest of the Utility of Inflammatory Biomarkers in Major Depression

    A comprehensive synopsis from Murdoch University reviews the current state of peripheral inflammatory biomarkers and their potential to improve the treatment and diagnosis of major depression.

    » Read this post

    Examining the role inflammatory biomarkers play in an upcoming COPD study

    ¬† This paper outlines the protocol for a clinical study aimed at determining whether roflumilast (a lon-acting inhibitor of the PDE-4 enzyme) can reduce the inflammation present in patients with moderate-to-severe COPD. As part of the study, biomarkers will be used to quantify the effect that roflumilast has on both systemic and pulmonary inflammation. Previous […]

    » Read this post

    Identifying Prognostic Biomarkers for Amyotrophic Lateral Sclerosis

    Using multiplex biomarker analysis, researchers at Penn State University aim to define a panel of prognostic ALS markers. ¬†This study shows the most meaningful results were obtained when combining biomarkers from CSF and plasma, rather than focusing on a single parameter. The combined plasma and CSF panel consists of six markers and accurately predicted the […]

    » Read this post

    Recorded Webinar: Quantitative Profiling of the Intrinsic Pathway of Apoptosis in Tumor Tissue using Myriad RBM’s Multiplex ApoptosisMAP™

    If you were unable to attend the webinar or would like to view the webinar again, a recorded version is now available for your convenience. View Recorded Webinar Learn about the creation of Myriad RBM’s fully validated, quantitative ApoptosisMAP and its application in cancer therapy research. The webinar highlights the main features of the service, […]

    » Read this post

    Using Renal Biomarkers to Advance Drug and Diagnostic Development in Kidney Disease

    Read this ebook, published by FierceBiotech, to learn how researchers are using new, more sensitive biomarkers to develop drugs and diagnostics in kidney disease.

    » Read this post